Patents Assigned to Peptech Limited
-
Publication number: 20110237780Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: January 18, 2011Publication date: September 29, 2011Applicant: Peptech LimitedInventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20080095767Abstract: The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions. The the framework regions are, or are derived from New World primate framework regions, and at least one of the CDRs is a non-New World primate CDR.Type: ApplicationFiled: August 1, 2007Publication date: April 24, 2008Applicant: Peptech LimitedInventors: Philip JENNINGS, Anthony Doyle, Adam Clarke, Robert Gay
-
Publication number: 20080031956Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.Type: ApplicationFiled: March 27, 2007Publication date: February 7, 2008Applicant: Peptech LimitedInventors: Timothy Trigg, John Walsh, Deborah Rathjen
-
Patent number: 7309689Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.Type: GrantFiled: March 25, 2004Date of Patent: December 18, 2007Assignee: Peptech LimitedInventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
-
Publication number: 20070202105Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.Type: ApplicationFiled: February 1, 2007Publication date: August 30, 2007Applicant: Peptech LimitedInventors: ANTHONY DOYLE, Benjamin Woolven, Jennifer Lee, Ian Tomlinson, Philip Jennings
-
Publication number: 20070077248Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: February 23, 2006Publication date: April 5, 2007Applicant: Peptech LimitedInventors: Deborah Rathjen, Roger Aston
-
Publication number: 20060204499Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: May 8, 2006Publication date: September 14, 2006Applicant: Peptech LimitedInventors: Deborah Rathjen, Roger Aston
-
Publication number: 20050276854Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.Type: ApplicationFiled: January 25, 2005Publication date: December 15, 2005Applicant: Peptech LimitedInventors: Timothy Trigg, John Walsh, Deborah Rathjen
-
Patent number: 6924309Abstract: The present invention relates to compounds of the general formula: NO2-A-B wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 carbon atoms and B is (CH2)n(COOH)m in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or of general formula (I), wherein A? is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B? is (CH2)j(COOH)k in which j is an integer from 1 to 3 and k is 0 or 1; and the derivatives thereof in which the hydrocarbon chain includes one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy. These compounds have biological activity, e.g. as anti-infective or anti-inflammatory agents.Type: GrantFiled: March 18, 2002Date of Patent: August 2, 2005Assignees: Children, Youth and Women's Health Service Incorporated, Peptech LimitedInventors: Antonio Ferrante, Christopher J. Easton, Ling Xia
-
Patent number: 6913761Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin. Such formulations provided release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.Type: GrantFiled: July 20, 1999Date of Patent: July 5, 2005Assignee: Peptech LimitedInventors: Timothy Elliot Trigg, John Desmond Walsh, Deborah Ann Rathjen
-
Publication number: 20040180832Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.Type: ApplicationFiled: March 25, 2004Publication date: September 16, 2004Applicant: Peptech LimitedInventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
-
Patent number: 6777386Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.Type: GrantFiled: November 26, 2001Date of Patent: August 17, 2004Assignee: Peptech LimitedInventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
-
Patent number: 6593458Abstract: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Leu63-Phe64-Lys65-Gly66-Gln67-Gly68-Cys69-Pro70-Ser71-Thr72-His73-Val74-Leu75-Leu76-Thr77-His78-Thr79-Ile80-Ser81-Arg82-Ile83 (peptide 304) of mature human TNF-&agr;. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-&agr; of amino acid resides 63-83. Antibodies or fragments thereof which bind particular regions of mature human TNF-&agr; are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.Type: GrantFiled: December 13, 2000Date of Patent: July 15, 2003Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Publication number: 20030064021Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.Type: ApplicationFiled: April 10, 2002Publication date: April 3, 2003Applicant: Peptech LimitedInventors: Deborah Ann Rathjen, Antonio Ferrante
-
Patent number: 6498237Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: December 24, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 6451983Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: September 17, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 6448380Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: September 10, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Publication number: 20020052320Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.Type: ApplicationFiled: November 26, 2001Publication date: May 2, 2002Applicant: Peptech LimitedInventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
-
Patent number: 6375928Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.Type: GrantFiled: June 21, 2000Date of Patent: April 23, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Antonio Ferrante
-
Patent number: 6211152Abstract: A pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, in vitro, it releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37° C. at a rate of about 2-80 &mgr;g/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment, particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.Type: GrantFiled: February 17, 1999Date of Patent: April 3, 2001Assignee: Peptech LimitedInventors: John D. Walsh, Timothy E. Trigg